Quick Search
Products MDR1 (Multi Drug Resistance Protein 1, ABC20, ATP Binding Cassette Subfamily B (MDR/TAP) Member 1, ABCB1, CD243, CLCS, GP170, P-Glycoprotein, P-gp, P Glycoprotein 1, PGY1)
| Catalogue number: | M2825-14Z |
| Reactivities: | Human, Mouse, Rat, Canine, Non-Human Primate |
| Hosts: | Mouse |
| Applications: | Flow Cytometry, Immunocytochemistry, Immunohistochemistry, Immunoprecipitation, Western Blot |
| Size: | 500ul |
| Form: | Supplied as a liquid in PBS, 1% BSA, 0.1% sodium azide. |
| P type: | Mab |
| Isotype: | IgG1 |
| Purity: | Purified by affinity chromatography. |
| References: | 1. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies: N. Kartner, et al.; Nature 316, 820 (1985). 2. A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines: H.S. Chan, et al.; Lab. Invest. 59, 870 (1988). 3. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies: A.H. Schinkel, et al.; Cancer Res. 51, 2628 (1991). 4. Comparison of an immunoperoxidase "sandwich" staining method and western blot detection of P-glycoprotein in human cell lines and sarcomas: K. Toth, et al.; Am. J. Pathol. 140, 1009 (1992). 5. New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues: K. Toth et al.; Am. J. Pathol. 144, 227 (1994). 6. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations: W.T. Beck, et al.; Cancer Res. 56, 3010 (1996). 7. MRP and MDR1 gene expression in primary breast carcinomas: M. Filipits, et al.; Clin. Cancer Res. 2, 1231 (1996). 8. P-glycoprotein expression and prognostic value in acute myeloid leukemia: L. Senent, et al.; Haematologica 83, 783 (1998). 9. Transport of doxorubicin in mast cell granules and the effect of the calcium antagonist verapamil: L. Candussio, et al.; Anticancer Res. 19, 1101 (1999). 10. Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport: E. Crivellato, et al.; Histochem. J. 31, 635 (1999). 11. Clinical significance of P-glycoprotein (P-gp) expression in childhood acute lymphoblastic leukemia. Results of a 6-year prospective study: C. Dhooge & B. De Moerloose; Adv. Exp. Med. Biol. 457, 11 (1999). 12. The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme: R. Durmaz, et al.; Clin. Neurol. Neurosurg. 101, 238 (1999). 13. Interferon a2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype: M.H. Frank & S. Pomer; J. Cancer. Res. Clin. Oncol. 125, 117 (1999). 14. A multidrug-resistant breast cancer cell line induced by weekly exposure to doxorubicin: S.M. Hahn, et al.; Int. J. Oncol. 14, 273 (1999).15. Characterization of cyclosporin A transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin: K. Kawazu, et al.; Invest. Ophtalmol. Vis. Sci. 40, 1738 (1999). 16. Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein: J.M. van Den Elsen, et al.; PNAS 96, 13679 (1999). 17. Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells: H. Wada, et al.; Exp. Hematol. 27, 99 (1999). 18. Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival: H. Yokoyama, et al.; Surg. Today 29, 1141 (1999). 19. P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries: M. Demeule, et al.; FEBS Lett. 466, 219 (2000). 20. Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity: M. Julien & P. Gros; Biochemistry 39, 4559 (2000). 21. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response: I.O. Ng, et al.; Am. J. Clin. Pathol. 113, 355 (2000). 22. Activation of the human P-glycoprotein ATPase by trypsin: S.L. Nuti, et al.; Biochemistry 39, 3424 (2000). 23. Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart: A. Rosati, et al.; Anticancer Res. 20, 3403 (2000). 24. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies: G.L. Scheffer, et al.; Cancer Res. 60, 5269 (2000) 25. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis: F. Thevenod, et al.; J. Biol. Chem. 275, 1887 (2000). 26. Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK(1) cell line and its resistant counterpart: G. Decorti, et al.; Biochem. Pharmacol. 61, 61 (2001). 27. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone: R. Yumoto, et al.; Drug. Metab. Dispos. 29, 145 (2001) |
| Additional info: | Recognizes an internal, highly conserved amino acid sequence (VQEALD and VQAALD) found in both protein isoforms, MDR1 P-glycoprotein at ~170kD and MDR3 P-glycoprotein at ~140kD; not species specific. Crossreactivity Proteins: a ~200kD protein which migrates in the same position as myosin and with C-erbB2 protein (p185c-erbB2). |
Get the Best Promotions
